|
|
|
|
|
|
|
|
|
28.07.26 - 13:03
|
Alkermes plc Reports Second Quarter 2026 Financial Results (Business Wire)
|
|
|
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended June 30, 2026. To view the detailed second quarter 2026 earnings press release and presentation, please visit the company's investor relations website at https://investor.alkermes.com.
Alkermes will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) today, to discuss these financial results and expectations, and provide an update on the company. The webcast may be accessed on the Investors section of Alkermes' website at https://investor.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. In addition, a replay of the conference call may be accessed by visiting Alkermes' website.
About Alkermes plc
Alkermes plc, a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfoli...
|
|
|
|
|
|
|
14.07.26 - 22:06
|
Alkermes to Report Second Quarter Financial Results on July 28, 2026 (Business Wire)
|
|
|
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, July 28, 2026 to discuss the company's second quarter financial results.
The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website.
About Alkermes plc
Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Alkermes' pipeline inc...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16.06.26 - 12:24
|
Alkermes′ alixorexton secures FDA and EC orphan designations (PBR)
|
|
|
The FDA granted the status to alixorexton for idiopathic hypersomnia while the EC approved the designation for narcolepsy. In the US, the ODD offers incentives such as tax
The post Alkermes' alixorexton secures FDA and EC orphan designations appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
|
|
|
|
|
|
26.05.26 - 13:03
|
Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting (Business Wire)
|
|
|
— Company to Present 11 Posters Demonstrating Commitment to Advancing Innovative Research for People Living With Chronic Psychiatric and Neurological Disorders —DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present clinical and real-world data related to the company's psychiatry and orexin portfolios at the American Society of Clinical Psychopharmacology Annual Meeting, taking place May 26-29, 2026 in Miami. The poster presentations include data related to Alkermes' proprietary commercial medicines, LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil), and its pipeline of investigational orexin 2 receptor agonists, including alixorexton, ALKS 4510 and ALKS 7290.
“Alkermes brings decades of experience advancing innovative medicines in neuroscience and psychiatry, underpinned by deep scientific expertise. Our poster presentations at ASCP reflect our continued commitment to advancing both the understanding of, and treatment options for, complex...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
